Rimonabant drug interactions | Litt's Drug Eruption and Reaction Database

Rimonabant comment watch save

TRADE NAME: Acomplia (Sanofi-Aventis)
INDICATIONS: Obesity
CLASS: Anti-obesity / weight loss pharmacotherapy, CB1 Cannabinoid receptor antagonist
HALF-LIFE: N/A

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Clarithromycin, Itraconazole, Ketoconazole, Nefazodone, Ritonavir, Telithromycin

See adverse reactions attributed to class:
Anti-obesity / weight loss pharmacotherapy

This drug has been withdrawn.

Please login to view the rest of this drug profile.

Page last updated 06/28/2025

Search drug eruptions and reactions data anytime, anywhere

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Hospitalization possible
Life threatening
Fatal

Breast feeding

Geriatric

Pediatric